RxDoctor Payments Data

Praveen Kamaraju, MD

Internal Medicine · Bay City, MINPI 1083687842

Payments from drug & device makers

$6,920in general payments, 2019–2025

Across 391 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$537
  • AstraZeneca$515
  • Lilly USA, LLC$388
  • Novo Nordisk$334
  • Pfizer$331
  • Amgen$303
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$6,70597%
  • Education$2153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,920 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$283,128
Medicare patients
584
Services billed
3,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$210,235
MounjaroTirzepatide62$108,607
TrulicityDulaglutide68$95,273
JardianceEmpagliflozin83$83,256
JanuviaSitagliptin Phosphate68$60,896
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$44,240
EntrestoSacubitril/Valsartan26$30,104
XareltoRivaroxaban60$27,668
FarxigaDapagliflozin Propanediol36$24,533
RexultiBrexpiprazole17$19,966
Atorvastatin Calcium1,212$16,602
Lantus SolostarInsulin Glargine,hum.Rec.Anlog137$16,160
XifaxanRifaximin16$15,074
Breo ElliptaFluticasone/Vilanterol37$14,865
BrilintaTicagrelor48$13,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$331$214,039273 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$388$207,802144 claims
Boehringer IngelheimJardiance$174$83,25683 claims
MerckJanuvia$276$60,89668 claims
GSKTrelegy Ellipta, Breo Ellipta$297$59,10590 claims
AstraZenecaFarxiga, Brilinta$515$38,49284 claims
NovartisEntresto$262$30,10426 claims
Johnson & JohnsonXarelto$267$27,66860 claims
Otsuka America Pharmaceutical, Inc.Rexulti$260$19,96617 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$114$15,07416 claims
Sumitomo Pharma America, Inc.Gemtesa$18$13,15443 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$78$6,46916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →